Please login to the form below

Not currently logged in
Email:
Password:

mutiple myeloma

This page shows the latest mutiple myeloma news and features for those working in and with pharma, biotech and healthcare.

Mixed cancer news from NICE

Mixed cancer news from NICE

Agency backs Janssen’s myeloma drug but denies Bayer’s Xofigo in prostate cancer. ... The cost-effectiveness agency issued draft guidance giving the green light to Janssen's Velcade in the treatment of certain patients with multiple myeloma in

Latest news

  • NICE denies early use of Janssen’s Velcade NICE denies early use of Janssen’s Velcade

    Draft guidance doesn't recommend expanded bone marrow cancer indication. Janssen's Velcade is not a cost-effective use of NHS resources for the early treatment of multiple myeloma, according to ... The drug is already recommended by NICE for use in

More from news
Approximately 2 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics